Proteomic Risk Model Guides Cardioprotective Therapy in Type 2 Diabetes Randomized Trial
Background
Type 2 Diabetes (T2D) affects nearly 600 million globally, with Cardiovascular Disease (CVD) remaining the leading cause of complications and death. Despite novel therapies like SGLT2 inhibitors and GLP-1 receptor agonists demonstrating proven cardioprotective benefits and guideline endorsement, their utilization remains critically low, reaching only 23% of eligible patients by 2023. This underutilization, driven by factors like physician awareness, insurance, and variable treatment responses, highlights a significant gap in care, leading to substantial healthcare costs and preventable mortality.
Why It Matters
This trial's approach to guiding cardioprotective therapy via a proteomic risk model could revolutionize how Type 2 Diabetes (T2D) patients receive crucial CVD prevention. If successful, such a model could precisely identify high-risk individuals, optimizing the prescription of SGLT2 inhibitors and GLP-1 receptor agonists and overcoming current underutilization barriers. Implementing a data-driven risk stratification could ensure the right patient gets the right therapy, reducing unnecessary exposure for lower-risk individuals while maximizing benefit for those most vulnerable. This could lead to more efficient healthcare resource allocation and significantly improve long-term cardiovascular outcomes for millions.
type-2-diabetes
cardiovascular-disease
proteomics
sglt2-inhibitors
glp-1-agonists
risk-stratification